Hims & Hers Health Inc. (NYSE: HIMS) is a healthcare company, listed on the NYSE. Alpha Stocks Insight tracks HIMS across all major catalysts: quarterly earnings reports, analyst upgrades and downgrades, mergers and acquisitions, regulatory decisions, and significant price moves driven by sector or macro developments. This page centralises 5 articles published since May 11, 2026, providing investors with timely, data-driven analysis of Hims & Hers Health Inc.'s financial performance and competitive position. New coverage is added each trading day.
Price
$28.09
Today
-14.20%
Mkt Cap
$6.5B
52W High
$70.43
52W Low
$13.74
Data via Finnhub · refreshes hourly · not financial advice
A $400M uncommitted facility from JPMorgan gives Hims & Hers new financial flexibility as it scales healthcare and pharmacy operations.
Barclays lifted its HIMS target from $29 to $39, citing GLP-1 momentum and a July FDA peptide ruling that analysts say could be the next major catalyst.
Telehealth company plans convertible senior notes offering to fund international growth and accelerate AI-driven platform capabilities.
Hims & Hers shares plummeted Tuesday after the telehealth provider reported a quarterly net loss and underwhelming earnings outlook.
Hims & Hers Health gained on Monday amid strategic moves into AI-driven care and GLP-1 medications. Analysts remain broadly constructive despite a wide 52-week range.
Important Legal Disclaimer
This is for informational purposes only and is not financial, investment, or tax advice. Past performance is no guarantee of future results. We are not licensed advisors. For Swiss residents: This does not constitute a public offer under FINSA. For EU residents: Not MiFID II compliant advice. For US residents: Not SEC-registered advice. Always consult a qualified professional. Investing involves risk of loss.
Affiliate disclosure: This site may contain affiliate links to brokerage platforms. If you open an account through one of our links, we may earn a commission at no additional cost to you. Affiliate relationships do not influence our editorial content or stock coverage decisions.
Important Legal Disclaimer: This is for informational purposes only and is not financial, investment, or tax advice. Past performance is no guarantee of future results. We are not licensed advisors. For Swiss residents: This does not constitute a public offer under FINSA. For EU residents: Not MiFID II compliant advice. For US residents: Not SEC-registered advice. Always consult a qualified professional. Investing involves risk of loss.